After a comprehensive search, we are excited to share that Emily Eldh has accepted the Director of the Office of Human Research Studies position, which includes oversight of the DFCI Institutional Review Board (IRB) and the DF/HCC Scientific Review Committees which serve the entire Dana-Farber/Harvard Cancer Center consortium.
Many of you know Emily from her years of service in the IRB. Emily brings a wealth of experience in the Human Research Protection arena having served as the Associate Director for Clinical Research and most recently as the Interim Director.
"I am honored to take the helm of OHRS during this time of major regulatory change with respect to the Federal Policy for the Protection of Human Subjects, also known as the Common Rule, and NIH policy on use of Single IRBs" expressed Emily.
Emily is a Certified IRB Professional as well as a participant in many national IRB organizations. Prior to joining OHRS, Emily served as the Clinical Trials Network Manager for the Dana-Farber/Partners Cancer Cancer Care Affiliate Program and the Cancer and Leukemia Group B (CALGB).
"It will be a demanding transition moving from the current IRB model to reliance on a system of different external IRBs, each with their own systems and policies. Through this change, OHRS will be the local resource facilitating communications with external IRBs. We want to be part of the solution that helps expedite the research review process without compromising humans subjects protection. With thoughtful planning and execution, I’m confident that we will meet this goal" Emily added.
Please join us in congratulating Emily on this well-deserved appointment!